ACM
AXSM icon

Atika Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Atika Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Buy
+63,000
New +$13.7M 1.01% 28
2026
Q1 		– Sell
-55,500
Closed -$10.1M – 64
2025
Q4 		$10.1M Buy
55,500
+6,500
+13% +$907K 1.07% 29
2025
Q3 		$5.95M Buy
49,000
+2,879
+6% +$324K 0.48% 50
2025
Q2 		$4.81M Sell
46,121
-27,579
-37% -$2.92M 0.48% 47
2025
Q1 		$8.6M Buy
73,700
+51,700
+235% +$5.89M 1.21% 26
2024
Q4 		$1.86M Sell
22,000
-35,000
-61% -$3.22M 0.2% 79
2024
Q3 		$5.12M Buy
57,000
+8,000
+16% +$698K 0.53% 57
2024
Q2 		$3.94M Sell
49,000
-19,000
-28% -$1.41M 0.39% 71
2024
Q1 		$5.43M Buy
68,000
+1,300
+2% +$109K 0.53% 63
2023
Q4 		$5.31M Sell
66,700
-4,300
-6% -$287K 0.71% 55
2023
Q3 		$4.96M Sell
71,000
-41,000
-37% -$3.06M 0.65% 53
2023
Q2 		$8.05M Sell
112,000
-43,000
-28% -$3.17M 0.81% 48
2023
Q1 		$9.56M Sell
155,000
-71,535
-32% -$4.7M 1.41% 23
2022
Q4 		$17.5M Sell
226,535
-37,795
-14% -$2.26M 2.51% 11
2022
Q3 		$11.8M Buy
264,330
+114,330
+76% +$5.71M 1% 45
2022
Q2 		$5.75M Buy
+150,000
New +$4.74M 0.65% 48

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Atika Capital Management's AXSM Position: Q2 2026 in Review

Atika Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 63,000 shares worth $15.4M. The stake represents 1.01% of the portfolio and ranks #28 among its holdings. This is a return to the name: Atika Capital Management previously reported a position in AXSM as recently as Q4 2025.

Atika Capital Management first reported a position in AXSM in Q2 2022 and has held it in 16 quarters since. The position peaked at $17.5M in Q4 2022. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Atika Capital Management held 63,000 shares of Axsome Therapeutics worth $15.4M as of Q2 2026.
  • Axsome Therapeutics was a new Atika Capital Management position in Q2 2026.
  • Axsome Therapeutics made up 1.01% of Atika Capital Management's portfolio in Q2 2026, its #28 holding.
  • Atika Capital Management first reported a position in Axsome Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • Atika Capital Management's Axsome Therapeutics position peaked at $17.5M in Q4 2022.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.